In vitro cleavage of hepatitis B virus C mRNA by 10-23 DNA enzyme

Hepatobiliary and Pancreatic Diseases International

Volumn 4, Issue 4, 2005, Pages 573-576

  Hou, Wei ^a   Wo, Jian Er ^a   Li, Min Wei ^a   Liu, Ke Zhou ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

10 23 DNA enzyme; C gene; Cleavage; Hepatitis B; In vitro

Indexed keywords

DEOXYRIBOZYME; MESSENGER RNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME SYNTHESIS; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HEPATITIS B VIRUS; IN VITRO STUDY; OPEN READING FRAME; RNA CLEAVAGE;

ANTIVIRAL AGENTS; BASE SEQUENCE; CODON; DNA PRIMERS; DNA, CATALYTIC; DNA, SINGLE-STRANDED; HEPATITIS B VIRUS; KINETICS; OPEN READING FRAMES; RNA, MESSENGER; RNA, VIRAL; SUBSTRATE SPECIFICITY; TRANSCRIPTION, GENETIC;

EID: 28444492705     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997;94:4262-4266.
2. Joyce GF. RNA cleavage by the 10-23 DNA enzyme. Methods Enzymol 2001;341:503-517.
3. Ritu G, Banerjea AC. Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: inhibition of the coreceptor function by DNA-enzyme. FEBS Lett 1998;436:233-238.
4. Zhang XY, Xu YN, Ling H, Hattori T. Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme. FEBS Lett 1999;458:151-156.
5. Sriram B, Banerjea AC. In vitro-selected RNA cleaving DNA enzymes from a combinatorial library are potent inhibitors of HIV-1 gene expression. Biochem J 2000;352:667-673.
6. Basu S, Sriram B, Goila R, Banerjea AC. Tergrted cleavage of HIV-1 coreceptor-CXCR-4 by RNA-cleaving DNA-enzyme: inhibition of coreceptor function. Antiviral Res 2000;46:125-134.
7. Unwalla H, Banerjea AC. Novel mono-and di-DNA-enzymes targeted to cleave TAT or TAT-REV RNA inhibit HIV-1 gene expression. Antiviral Res 2001;551:127-139.
8. Unwalla H, Banerjea AC. Inhibition of HIV-1 gene expression by novel macrophage-tropic DNAenzymes targeted to cleave HIV-1 TAT/Rev RNA. Biochem J 2001;357:147-155.
9. Chakraborti S, Banerjea AC. Inhibition of HIV-1 gene expression by noval DNA enzymes targeted to cleave HIV-1 TAR RNA: potential effectiveness against all HIV-1 isolates. Mol Ther 2003;7:817-826.
10. Chakraborti S, Banerjea AC. Identification of cleavage sites in the HIV-1 TAR RNA by 10-23 and 8-17 catalytic motif containing DNA enzymes. Biomacromolecules 2003;4:568-571.
11. Dash BC, Banerjea AC. Sequence-specific cleavage activities of DNA enzymes targeted against HIV-1 Gag and Nef regions. Oligonucleotides 2004;14:41-47.
12. Schubert S, Fürste JP, Werk D, Grunert HP, Zeichhardt H, Erdmann VA, et al. Gaining target access for deoxyribozymes. J Mol Biol 2004;339:355-363.
13. Takahashi H, Hamazaki H, Habu Y, Hayashia M, Abe T, Miyano-Kurosaki N, et al. A new modified DNA enzyme that targets influenza virus A mRNA inhibit viral infection in cultured cells. FEBS Lett 2004;560:69-74.
14. Wo JE, Wu XL, Zhu HH, Zhou LF, Yao HP, Chen LW. DNAzymes in vitro inhabit the expression of hepatitis B virus genes. J Zhejiang University (Medical Science) 2003;32:112-115.
15. Breaker RR. Making catalytic DNAs. Science 2000;290:2095-2096.
16. Breaker RR. Natural and engineered nucleic acids as tools to explore biology. Nature 2004;432:838-845.
17. Silverman SK. Breaking up is easy to do (If you're a DNA enzyme that cleaves RNA). Chem Bio 2004;11:7-8.
18. Elizabeth F. DNA cuts its teeth-as an enzyme. Science 1999; 286:2441-2442.
19. Mitchell A, Dass CR, Sun LQ, Khachigian LM. Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Res 2004;32: 3065-3069.
20. Zhang FK. Interferon-alfa in the treatment of chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2004;3:337-340.
21. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004;30:115-133.
22. Sun PH, Nam KK, Seong GH, Hyun JC, SukJoon K, Jin HH, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004;40:837-844.
23. Pas SD, Noppornpanth S, Eijk AA, Man RA, Niesters HGM. Quantification of the newly detected lamivudine resistant YSDD variants of Hepatitis B virus using molecular beacons. J Clin Virol 2005;32:166-172.
24. Khachigian LM. Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. J Clin Invest 2000;106:1189-1195.
25. Dass CR. Deoxyribozymes: cleaving a path to clinical trials. Trends Pharmacol Sci 2004;25:395-397.
26. Schubert S, Kurreck J. Ribozymes- and deoxyribozyme-strategies for medical applications. Curr Drug Targets 2004;5:667-681.
27. Achenbach JC, Chiuman W, Cruz RP, Li Y. DNAzymes: from creation in vitro to application in vivo. Curr Pharm Biotechnol 2004;5:321-336.
28. Peracchi A. Prospects for antiviral ribozymes and deoxyribozymes. Rev Med Virol 2004;14:47-64.